TuHURA Biosciences, Inc. disclosed unaudited pro forma condensed combined financial information in their latest filing.
The financial data includes the combination of Kintara, TuHURA, and Kineta adjusted for recent transactions.
The filing details the reverse merger completed on October 18, 2024, and subsequent business combinations.
Reverse Merger
Legacy TuHURA was the accounting acquirer and Kintara the acquired company, leading to a reverse recapitalization. No goodwill or intangible assets were recorded.
Business Combination
TuHURA acquired Kineta, including rights to the novel KVA12123 antibody, through a series of mergers completed on June 30, 2025.
Accounting Method
The mergers were accounted for as a business combination using the acquisition method of accounting in accordance with U.S. GAAP.
- The combination of financial data provides investors with a comprehensive view of TuHURA's financial position post-mergers.
- The disclosure enhances transparency and assists stakeholders in understanding the impact of recent transactions on TuHURA's financial outlook.
TuHURA's pro forma financial information reflects the successful completion of key transactions and sets the stage for future growth and development.